- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00871351
Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)
Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached the following lipid management target values during treatment: Category I (low-risk group) with no other risk factors - LDL-C <160 mg/dL; Category II (mid-risk group) with 1-2 risk factors other than LDL-C levels - LDL-C <140 mg/dL; Category III (high-risk group) with 3 or more other risk factors - LDL-C <120 mg/dL; and for participants with history of coronary artery disease - LDL-C <100 mg/dL.
- outpatient men or women, age 20 years and older
Exclusion Criteria:
- fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dL.
- homozygous familial hypercholesterolemia.
- creatine phosphokinase (CPK) >2 times the upper limit of normal (X ULN) at start of washout or treatment period.
- glycosylated hemoglobin (HbA1c) >=8% at start of washout or treatment period.
- severe hepatic function disorder, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2X ULN at start of washout or treatment period.
- hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets.
- pregnant or lactating
- discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.)
- cyclosporine treatment
- hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis.
- hyperlipidemia associated with drug administration that causes adverse serum lipid effects.
- participation in a clinical study within 4 weeks of washout
- cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ezetimibe + Atorvastatin
Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
|
1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
Other Names:
1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
|
Active Comparator: Atorvastatin
Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
|
1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
|
Active Comparator: Rosuvastatin
Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
|
1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values
Time Frame: End of Week 4 to Week 16 or discontinuation
|
LDL-C was measured before group study drug administration (Week 4, end of atorvastatin single therapy) and at the end of study drug administration (after 12 weeks of study drug treatment, or at discontinuation).
|
End of Week 4 to Week 16 or discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in LDL-C
Time Frame: End of washout period to Week 16 or discontinuation
|
LDL-C was measured at the start of the atorvastatin 10 mg treatment period (end of the washout period) and at the end of administration of the study drug (Week 16 or discontinuation).
|
End of washout period to Week 16 or discontinuation
|
Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values
Time Frame: Week 16 or discontinuation
|
LDL-C was measured at the end of administration of the study drug (Week 16 or discontinuation). Target values: For participants with history of coronary artery disease: <100 mg/dL; for participants with at least 3 cardiovascular (CV) risk factors: <120 mg/dL; for participants with 1-2 CV risk factors: <140 mg/dL; for participants with no CV risk factors: <160 mg/dL. |
Week 16 or discontinuation
|
Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)
Time Frame: End of Week 4 to Week 16 or discontinuation
|
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at 4 weeks after the start of the treatment period (after completion of administration of atorvastatin 10 mg alone) and at Week 16 or at discontinuation.
|
End of Week 4 to Week 16 or discontinuation
|
Percent Change in Total Lipids and Hs-CRP
Time Frame: End of washout to Week 16 or discontinuation
|
Total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and hs-CRP were measured at the start of the treatment period (at start of administration of atorvastatin 10 mg alone) and at the end of study drug (Week 16 or discontinuation).
|
End of washout to Week 16 or discontinuation
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Hypercholesterolemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Atorvastatin
- Rosuvastatin Calcium
- Ezetimibe
Other Study ID Numbers
- P06027
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Hypercholesterolemia
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineCompletedPrimary HypercholesterolemiaUnited States
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Sun Yat-sen UniversityActive, not recruiting
-
Organon and CoMerck Sharp & Dohme LLCCompleted
-
Organon and CoCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedPrimary Hypercholesterolemia
Clinical Trials on Ezetimibe
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Bronx VA Medical CenterCompletedHypercholesterolemiaUnited States
-
Korea UniversityWithdrawn
-
GlaxoSmithKlineCompleted
-
NewAmsterdam PharmaCompletedDyslipidemias | Hypercholesterolemia | High CholesterolUnited States
-
Cao YuRecruiting
-
The Affiliated Hospital of Qingdao UniversityCompleted